Boryeong Collaborates with AI Drug Venture to Expand 'Kanab' Indications Through Joint Research

AI New Drug Venture Company Oncocross Partners Up

Boryung announced on the 24th that it has signed a joint research and development agreement with Oncocross, an artificial intelligence (AI) new drug venture company, to expand the indications of the hypertension treatment drug 'Kanarb (generic name Pimasartan)'.

Boryeong headquarters exterior.
Photo by Boryeong

Through this contract, the two companies plan to discover new indications for Kanarb by utilizing Oncocross's AI platform, 'RAPTOR AI'. RAPTOR AI is an AI drug development platform that identifies the optimal indications for drugs and can be used to explore new indications for drugs under development or already approved, as well as to derive combination therapies.

RAPTOR AI discovers indications by comparing gene expression patterns based on patient and disease big data owned by Oncocross, enabling fast results with high accuracy and low cost. In fact, RAPTOR AI has achieved results by discovering several new drug candidates, including treatments for sarcopenia, and conducting clinical trials.

Kanarb, a hypertension new drug developed independently by Boryung, has continuously made efforts to add indications through various clinical studies. In 2021, Boryung expanded Kanarb's indications to include proteinuria reduction and broadened the age range of use through clinical research. The Kanarb family achieved prescription sales of 141.8 billion KRW last year, ranking first among domestic new drugs in prescriptions.

Kim Irang, CEO of Oncocross, said, "We will do our best to ensure that AI technology contributes to expanding drug indications," and added, "We will strive to make this a representative cooperation case where AI biotech and pharmaceutical companies mutually benefit."

Boryung CEO Jang Doohyun stated, "Thanks to Oncocross's innovative AI technology, the discovery of new indications for Kanarb has gained more momentum," and said, "Based on close cooperation between the two companies, we will promptly expand Kanarb's indications to provide more diverse treatment options."

This content was produced with the assistance of AI translation services.